Results 1 to 10 of about 1,874,188 (207)

An overview of VaxchoraTM, a live attenuated oral cholera vaccine [PDF]

Human Vaccines & Immunotherapeutics, 2020
Cholera remains a public health threat among the least privileged populations and regions affected by conflicts and natural disasters. Together with Water, Sanitation and Hygiene practices, use of oral cholera vaccines (OCVs) is a key tool to prevent ...
Tarun Saluja, Vijayalaxmi V. Mogasale, Jean-Louis Excler, Jerome H. Kim, Vittal Mogasale   +4 more
doaj   +3 more sources

Uptake likelihood assessment of oral cholera vaccine capsules: insights from stakeholder consultations in five countries [PDF]

BMC Public Health
Background The global resurgence of cholera, a diarrhoeal disease, has resulted in vaccine demand that exceeds the currently available supply resulting in global calls for next generation cholera vaccines.
Dijana Spasenoska, Anna-Lea Kahn, Malika Bouhenia, Naveena Aloysia D’Cor, Jung-Seok Lee, Se Eun Park, Julia Lynch   +6 more
doaj   +3 more sources

The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicity [PDF]

Frontiers in Immunology
Cholera has re-emerged as a major global public health threat. Orally administered attenuated or inactivated vaccines offer protection against enteric pathogens such as Vibrio cholerae, and several World Health Organization-prequalified oral cholera ...
A. Louis Bourgeois, A. Louis Bourgeois, Daniel A. Scott, Shahida Baqar, Shahida Baqar, David R. Tribble, David R. Tribble, Ann-Mari Svennerholm, Richard I. Walker   +8 more
doaj   +2 more sources

Development of DuoChol, a Thermostable Inactivated Whole-Cell/B-Subunit Oral Cholera Vaccine in Enteric Capsule [PDF]

Vaccines
Background/Objectives: Cholera remains an important global health problem. Inactivated oral cholera vaccines (OCVs) are essential in the WHO/GTFCC (World Health Organization/Global Task Force on Cholera Control) strategy to end cholera by 2030; however ...
Manuela Terrinoni, Michael R. Lebens, Stefan L. Nordqvist, Frida Nilsson, Madeleine Löfstrand, Julia Lynch, Jan Holmgren   +6 more
doaj   +2 more sources

Effectiveness of two doses of Euvichol-plus oral cholera vaccine in response to the 2017/2018 outbreak: a matched case–control study in Lusaka, Zambia [PDF]

BMJ Open, 2022
Introduction Zambia experienced a major cholera outbreak in 2017–2018, with more than 5905 cases reported countrywide, predominantly from the peri-urban slums of Lusaka city.
Victor M Mukonka, Modest Mulenga, C Michelo, Khozya Zyambo, Cephas Sialubanje, Muzala Kapina, Orbrie Chewe, Belem Blamwell Matapo, Albertina Moraes Ngomah, Brittany Gianetti, William Ngosa, Mpanga Kasonde, Kunda Musonda, Nyambe Sinyange, Patricia Bobo, Lucy Mazyanga, Nathan Bakyaita   +16 more
doaj   +2 more sources

Knowledge and perception of a clinical trial among the participants: An experience from oral cholera vaccine study in Koshi Province, Nepal [PDF]

Human Vaccines & Immunotherapeutics
Clinical trials (CT) have been the cornerstones in developing medicines, vaccines, and new interventions. Despite tremendous efforts, a CT cannot succeed without participants’ involvement. Various factors can affect people’s attitude and participation in
Shipra Chaudhary, Surendra Uranw, Basant Rai, Nisha Keshary Bhatta, Gauri Shankar Shah, Prakash Poudel, Basudha Khanal, Rosan Prasad Shah Kalawar, Nikita Rai, Jenisha Shrestha, Merina Shrestha, Shalu Parajuli, Birendra Prasad Gupta, Sridhar Vemula, Katerina Rok Song, Julia Lynch, Tarun Saluja   +16 more
doaj   +2 more sources

Epidemiologic and Genomic Surveillance of Vibrio cholerae and Effectiveness of Single-Dose Oral Cholera Vaccine, Democratic Republic of the Congo [PDF]

Emerging Infectious Diseases
We conducted 4 years of epidemiologic and genomic surveillance of single-dose effectiveness of a killed whole-cell oral cholera vaccine (kOCV) and Vibrio cholerae transmission in the Democratic Republic of the Congo.
Christine Marie George, Alves Namunesha, Kelly Endres, Willy Felicien, Presence Sanvura, Jean-Claude Bisimwa, Jamie Perin, Justin Bengehya, Jean Claude Kulondwa, Ghislain Maheshe, Cirhuza Cikomola, Lucien Bisimwa, Alain Mwishingo, David A. Sack, Daryl Domman   +14 more
doaj   +2 more sources

Study protocol for cholera vaccination as a model to measure the inflammatory response in the gut: A case of modulation with a Lactobacillus plantarum K8 lysate

PLoS ONE, 2023
It is crucial for human health that the immune system of the gastrointestinal tract works effectively. Dietary modulation is one of the factors that regulate the immune response in the gut. This study aims to develop a safe human challenge model to study
Min Young Park, Soo-yeon Park, Anita Hartog, Els van Hoffen, Alwine Kardinaal, Joohee Kim, Hee Jung Choi, Oran Kwon, Ji Yeon Kim   +8 more
doaj   +2 more sources

Methods to assess the impact of mass oral cholera vaccination campaigns under real field conditions. [PDF]

PLoS ONE, 2014
There is increasing interest to use oral cholera vaccination as an additional strategy to water and sanitation interventions against endemic and epidemic cholera.
Jacqueline Deen, Mohammad Ali, David Sack   +2 more
doaj   +1 more source

Immunogenicity of cholera vaccination in children with inflammatory bowel disease

Human Vaccines & Immunotherapeutics, 2021
The cholera vaccine can protect patients with inflammatory bowel disease (IBD) against both cholera and travelers’ diarrhea. However, both immunosuppressive treatment and IBD can affect its vaccine immunogenicity.
Łukasz Dembiński, Anna Stelmaszczyk-Emmel, Katarzyna Sznurkowska, Agnieszka Szlagatys-Sidorkiewicz, Andrzej Radzikowski, Aleksandra Banaszkiewicz   +5 more
doaj   +1 more source